NEW YORK (GenomeWeb) – Labcyte today announced it has extended its collaboration with the University of Helsinki's Institute for Molecular Medicine Finland (FIMM) to use the firm's Echo liquid handling technology for personalized oncology.
Under the terms of the collaboration, FIMM's High Throughput Biomedicine Unit will test the firm's latest liquid handlers in genomic and proteomic applications downstream of drug sensitivity testing, and incorporate the technology into a range of workflows including high-content screening, reverse-phase protein arrays, next-generation sequencing, RNA sequencing, gene expression analysis, and genotyping.
Labcyte's acoustic liquid handling technology uses sound waves to transfer reagents, providing faster and more accurate results than traditional methods, the firm said in a statement.
"The Echo liquid handlers have been essential to pushing forward with multiple programs at FIMM, the biggest being our personalized cancer treatment program, which is totally reliant on having acoustic dispensers," said Krister Wennerberg, head of the High Throughput Biomedicine Unit at FIMM, said in a statement.
Labcyte's collaboration with FIMM for personalized medicine applications began in 2013.